How Blood Pressure Target Data At Mineralys Therapeutics (MLYS) Has Changed Its Investment Story

• Mineralys Therapeutics reported new analyses from the pivotal Phase 3 Launch-HTN trial showing 46% of lorundrostat treated patients hit AHA/ACC systolic blood pressure targets at 12 weeks, alongside supportive Explore-OSA Phase 2 data in hypertensive adults with obstructive sleep apnea.
• The breadth of late stage data around lorundrostat, including six completed trials and detailed blood pressure and sleep related endpoints, points to a maturing clinical package that could reshape how Mineralys Therapeutics positions its lead asset in difficult to treat hypertension and related comorbidities.
• We will now assess how Mineralys Therapeutics' Phase 3 Launch HTN result of 46% target blood pressure attainment could influence the investment narrative.

Scan other late stage healthcare stories moving on clinical data like Mineralys Therapeutics by reviewing the hand picked 34 healthcare AI stocks that could be next in focus.

Mineralys Therapeutics Investment Narrative Recap

Mineralys Therapeutics is still essentially a single asset story. To be comfortable as a shareholder, you need to believe lorundrostat can move from a late stage program to an approved product in uncontrolled and resistant hypertension, then later into cardiorenal comorbidities. The 46% target blood pressure attainment at 12 weeks adds clinical color, but the main near term catalyst remains progress toward an NDA filing and regulatory feedback.

The biggest risk is unchanged. Lorundrostat is not approved, Mineralys has no revenue, and the business is spending to build out commercial readiness while reporting losses, including a US$36.9 million loss in Q3 2025. If regulators ask for more data or launch timing slips, cash that is currently guided to last into 2028 may need to stretch further, which could increase the chance of future dilution.

The latest Launch HTN analysis is the announcement that matters most today because it directly feeds into how regulators, payers and clinicians may view lorundrostat in difficult to treat hypertension. A 46% rate of patients reaching AHA or ACC blood pressure targets at week 12 in a population already on two to five drugs helps frame the real world relevance of previous systolic blood pressure reduction data.

Regarding catalysts, this kind of detailed readout supports the NDA package in uncontrolled and resistant hypertension and can influence how Mineralys Therapeutics presents the opportunity to potential partners. It also connects to the broader program in obstructive sleep apnea, chronic kidney disease and other aldosterone driven conditions, since consistent effects across Launch HTN and Explore OSA would strengthen the case for label expansion, although those extensions still carry execution and regulatory risk.

Mineralys Therapeutics' current analyst narrative points to forecast revenue of US$467.2 million and earnings of US$16.6 million by 2029, from earnings today of a US$349.6 million loss. This implies an earnings swing of roughly US$366 million alongside a very large implied revenue ramp from a zero base.

Uncover why Mineralys Therapeutics' fair value indicates a 108% potential upside to its current price that could narrow quickly.

Exploring Other Perspectives

For a contrasting take, look at how the most cautious analysts treat the competitor risk around Mineralys Therapeutics. They were only penciling in about US$178.0 million of revenue and US$30.2 million of earnings by 2029, far below consensus. That more pessimistic story could shift meaningfully as the 46% Launch HTN result filters into fresh models, so it is worth exploring both narratives before you decide how this fits your own view.

Explore 3 other Mineralys Therapeutics fair value estimates, including one that suggests it could be worth just $48.50!

Reach Your Own Conclusion

Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

• A great starting point for your Mineralys Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• See our latest analysis for Mineralys Therapeutics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Mineralys Therapeutics' overall financial health at a glance.

Looking for more investment ideas beyond Mineralys Therapeutics?

Once you have a handle on Mineralys Therapeutics, it can help to line it up against other opportunities and see how it stacks up on quality, balance sheet strength and return potential. The Simply Wall St Screener is built for that kind of comparison, and these curated lists are an efficient way to expand your watchlist.

• If capital preservation sits high on your list, start with a group of 31 resilient stocks with low risk scores that score well on resilience and risk controls.
• For investors who care most about financial strength, scan the list of solid balance sheet and fundamentals (25 results) and focus on businesses with cleaner leverage and healthier cash positions.
• If you want ideas that are still off most radars, sift through a curated pool of 20 high quality undiscovered gems and see which stories you want to research next.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com